H. Lee Moffitt Cancer Center & Research Institute

Physician, Faculty, and Staff

Tawee Tanvetyanon, MD

Tawee Tanvetyanon, MD

Faculty Rank:

Assistant Member

Titles:

Department/Program Affiliations:

  • Head & Neck Oncology  
  • Thoracic Oncology  
  • Health Outcomes & Behavior  

Primary Address:

H. Lee Moffitt Cancer Center &
Research Institute
12902 Magnolia Drive
Tampa, FL 33612

USF Affiliations/College Department:

  • Medicine / Oncologic Sciences
  • Medicine / Internal Medicine

University Academic Rank:

Assistant Professor

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Tawee Tanvetyanon, MD

Education & Training:

  • M.D., Chulalongkorn University in Bangkok, Thailand, 1996
  • Internship, Albert Einstein Medical Center at Thomas Jefferson Medical College, Pennsylvania, 1998
  • Residency, Albert Einstein Medical Center at Thomas Jefferson Medical College, Pennsylvania, 2000
  • Fellowship, Loyola University Chicago, Stritch School of Medicine, Illinois, 2005 - Medicla Oncology & Hematology

General Board Certification / SubSpecialty:

  • Internal Medicine / Hematology
  • Internal Medicine / Medical Oncology

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Tawee Tanvetyanon, MD

Research Interests:

Dr. Tanvetyanon focuses his research on the improvement of supportive care and patient quality of life. His main interest lies in overcoming multi-faceted problems pertaining to the administration of current available therapies including chemotherapy, radiotherapy, surgery, and supportive care. His research has investigated symptoms associated with cancer and its treatment, including cancer-related bone disease, anemia and fatigue during concurrent chemo-radiotherapy for head and neck cancers, underutilization of erectile dysfunction management, and outpatient treatment of blood clotting disorders. His ongoing research includes exploring the benefit of PET scanning during neoadjuvant chemotherapy for lung cancer. Neoadjuvant chemotherapy or the administration of chemotherapy prior to definitive surgery is an area under active investigation for potentially improving long-term survival. Dr. Tanvetyanon is also a clinical investigator of the Southwest Oncology Co-operative Group currently with many active clinical trials.


Clinical Interests:

Dr. Tanvetyanon's effort is directed toward pallate cancer and treatment-related distress. Additional attention is given to those patients with multiple co-morbidities, impaired physical function, advanced age, or advanced disease. Dr. Tanvetyanon specializes in both Thoracic malignancies (lung cancer, mesothelioma, thymoma) and cancers of the head and neck.

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Tawee Tanvetyanon, MD

Publications:

  1. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Mar;28(8):1387-1394. Pubmedid: 20142592.   Pubmed ID: 20142592

  2. Tanvetyanon T, Robinson L, Sommers KE, Haura E, Kim J, Altiok S, Bepler G. Relationship between Tumor Size and Survival among Patients with Resection of Multiple Synchronous Lung Cancers. J Thorac Oncol. 2010 Jul;5(7):1018-1024. Pubmedid: 20453687.   Pubmed ID: 20453687

  3. Tanvetyanon T, Murtagh R, Bepler G. Rupture of a cerebral arteriovenous malformation in a patient treated with bevacizumab. J Thorac Oncol. 2009 Feb;4(2):268-269. Pubmedid: 19179909.   Pubmed ID: 19179909

  4. Tanvetyanon T, Padhya T, McCaffrey J, Zhu W, Boulware D, Deconti R, Trotti A. Prognostic Factors for Survival After Salvage Reirradiation of Head and Neck Cancer. J Clin Oncol. 2009 Apr;27(12):1983-1991. Pubmedid: 19289616.   Pubmed ID: 19289616

  5. Tanvetyanon T, Qin D, Padhya T, Kapoor R, McCaffrey J, Trotti A. Survival outcomes of squamous cell carcinoma arising from sinonasal inverted papilloma: report of 6 cases with systematic review and pooled analysis. Am J Otolaryngol. 2009 Jan;30(1):38-43. Pubmedid: 19027511.   Pubmed ID: 19027511

  6. Tanvetyanon T, Qin D, Padhya T, McCaffrey J, Zhu W, Boulware D, DeConti R, Trotti A. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg. 2009 Jul;135(7):687-692. Pubmedid: 19620591.   Pubmed ID: 19620591

  7. Tanvetyanon T. Quality-of-care indicators for non-small cell lung cancer. Cancer Control. 2009 Oct;16(4):335-341. Pubmedid: 19910920.   Pubmed ID: 19910920

  8. Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol. 2008 Oct;3(10):1112-1118. Pubmedid: 18827606.   Pubmed ID: 18827606

  9. Tanvetyanon T, Bepler G. Beta-carotene in multivitamins and the possible risk of lung cancer among smokers versus former smokers: a meta-analysis and evaluation of national brands. Cancer. 2008 Jul;113(1):150-157. Pubmedid: 18429004.   Pubmed ID: 18429004

  10. Tanvetyanon T, Eikman EA, Sommers E, Robinson L, Boulware D, Bepler G. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer. J Clin Oncol. 2008 Oct;26(28):4610-4616. Pubmedid: 18824709.   Pubmed ID: 18824709

  11. Tanvetyanon T, Robinson L, Schell M, Strong V, Kapoor R, Coit D, BeplerG. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrena metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol. 2008 Mar;26(7):1142-1147. Pubmedid: 18309950.   Pubmed ID: 18309950

  12. Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007 Jul;25(19):2741-2746. Pubmedid: 17602079.   Pubmed ID: 17602079

  13. Tanvetyanon T, Soares H, Djulbegovic B, Jacobsen P, Bepler G. A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol. 2007 Dec;2(12):1091-1097. Pubmedid: 18090580.   Pubmed ID: 18090580

  14. Tanvetyanon T, Choudhury A. Physician practice in the discontinuation of statins among patients with advanced lung cancer. J Palliat Care. 2006 Win;22(4):281-285. Pubmedid: 17263055.   Pubmed ID: 17263055

  15. Tanvetyanon T, Choudhury A. Severity, risk factors, and physician practices in the management of anemia during concurrent chemoradiation for head and neck carcinoma. Cancer. 2006 Apr;106(7):1554-1559. Pubmedid: 16518817.   Pubmed ID: 16518817

  16. Tanvetyanon T, Garrity E, Albain K. Acute lung injury associated with vinorelbine. J Clin Oncol. 2006 Apr;24(12):1952-1953. Pubmedid: 16622272.   Pubmed ID: 16622272

  17. Tanvetyanon T, Stiff P. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006 Jun;17(6):897-907. Pubmedid: 16547070.   Pubmed ID: 16547070

  18. Tanvetyanon T. Understanding the uncommon thoracic tumors. Cancer Control. 2006 Oct;13(4):252-253. Pubmedid: 17075561.   Pubmed ID: 17075561

  19. Tanvetyanon T, Clark J, Campbell S, Lo S. Neoadjuvant therapy: an emerging concept in oncology. South Med J. 2005 Mar;98(3):338-344. Pubmedid: 15813161.   Pubmed ID: 15813161

  20. Tanvetyanon T, Elmishad A, Carbone M. Development of malignant mesothelioma during treatment for prolymphocytic leukemia: is asbestos or simian virus 40 a link. Anticancer Res. 2005 Jan;25(1B):429-433. Pubmedid: 15816607.   Pubmed ID: 15816607

  21. Tanvetyanon T, Hines E J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. Cancer. 2005 Apr;103(8):1756-1757. Pubmedid: 15751014.   Pubmed ID: 15751014

  22. Tanvetyanon T, Stiff P. Recurrent steroid-responsive pancreatitis associated with myelodysplastic syndrome and transformations. Leuk Lymphoma. 2005 Jan;46(1):151-154. Pubmedid: 15621795.   Pubmed ID: 15621795

  23. Tanvetyanon T. Medical costs associated with chiropractic care. Arch Intern Med. 2005 Jun;165(11):1313-1314. Pubmedid: 15956016.   Pubmed ID: 15956016

  24. Tanvetyanon T. Molecular prediction of recurrence of breast cancer. N Engl J Med. 2005 Apr;352(15):1605-1607. Pubmedid: 15832454.   Pubmed ID: 15832454

  25. Tanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer. 2005 Jan;103(2):237-241. Pubmedid: 15597384.   Pubmed ID: 15597384

  26. Tanvetyanon T. Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2005 Jan;97(1):70-70. Pubmedid: 15632382.   Pubmed ID: 15632382

  27. Tanvetyanon T. Reply to the article "The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer" by K.P. Weinfurt et al. (Ann Oncol 2005; 16: 579-584). Ann Oncol. 2005 Oct;16(10):1712-1713. Pubmedid: 15972282.   Pubmed ID: 15972282

  28. Tanvetyanon T. Talking about death with dying children. N Engl J Med. 2005 Jan;352(1):91-92. Pubmedid: 15635780.   Pubmed ID: 15635780

  29. Tanvetyanon T. Treatment of localized lymphoma. N Engl J Med. 2005 Jun;352(23):2449-2451. Pubmedid: 15944432.   Pubmed ID: 15944432

  30. Nand S, Tanvetyanon T. Proton pump inhibitors and iron deficiency: is the connection real. South Med J. 2004 Sep;97(9):799-799. Pubmedid: 15455957.   Pubmed ID: 15455957

  31. Tanvetyanon T, Choudhury A. Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade. J Urol. 2004 Apr;171(4):1627-1627. Pubmedid: 15017238.   Pubmed ID: 15017238

  32. Tanvetyanon T, Choudhury A. Hypocalcemia and azotemia associated with zoledronic acid and interferon alfa. Ann Pharmacother. 2004 Mar;38(3):418-421. Pubmedid: 14970365.   Pubmed ID: 14970365

  33. Tanvetyanon T, Nand S. Herpes zoster during treatment with arsenic trioxide. Ann Hematol. 2004 Mar;83(3):198-200. Pubmedid: 15064871.   Pubmed ID: 15064871

  34. Tanvetyanon T, Nand S. Pancytopenia in hereditary haemorrhagic telangiectasia. Br J Haematol. 2004 Nov;127(4):371-371. Pubmedid: 15521911.   Pubmed ID: 15521911

  35. Tanvetyanon T, Ratanatharathorn V, Leopairat J. Mucoepidermoid carcinoma of the lung presenting as a cavitary lesion. J Med Assoc Thai. 2004 Aug;87(8):988-991. Pubmedid: 15471307.   Pubmed ID: 15471307

  36. Tanvetyanon T, Stiff P. Second allogeneic transplantation using a reduced-intensity preparative regimen for relapsed myelofibrosis. Am J Hematol. 2004 Oct;77(2):204-205. Pubmedid: 15389913.   Pubmed ID: 15389913

  37. Tanvetyanon T, Toor A, Stiff P. Post-transplant air-leak syndrome. Br J Haematol. 2004 Sep;126(6):758-758. Pubmedid: 15352978.   Pubmed ID: 15352978

  38. Tanvetyanon T. Adjuvant treatment of breast cancer with exemestane. N Engl J Med. 2004 Jul;351(1):100-102. Pubmedid: 15237463.   Pubmed ID: 15237463

  39. Tanvetyanon T. Arterial thrombosis in systemic lupus erythematosus. N Engl J Med. 2004 Oct;351(18):1910-1911. Pubmedid: 15515221.   Pubmed ID: 15515221

  40. Tanvetyanon T. HER-2 and fluorescent in situ hybridization to evaluate breast cancer. JAMA. 2004 Jul;292(3):328-328. Pubmedid: 15265845.   Pubmed ID: 15265845

  41. Tanvetyanon T. Is hypocalcemia during therapy with zoledronic acid or other bisphosphonatesbeneficial to cancer patients. Med Hypotheses. 2004;63(4):764-765. Pubmedid: 15325030.   Pubmed ID: 15325030

  42. Tanvetyanon T. Re: Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol. 2004 Nov;172(5 Pt 1):2082-2082. Pubmedid: 15540794.   Pubmed ID: 15540794

  43. Tanvetyanon T. Screening for primary human immunodeficiency virus infection. Arch Intern Med. 2004 Mar;164(6):680-680. Pubmedid: 15037504.   Pubmed ID: 15037504

  44. Tanvetyanon T. Telephone psychotherapy and care management for depression. Jama. 2004 Dec;292(22):2720le-2720le. Pubmedid: 15585725.   Pubmed ID: 15585725

  45. Tanvetyanon T. Treatment of von Willebrand's Disease. N Engl J Med. 2004 Nov;351(22):2345-2346. Pubmedid: 15570685.   Pubmed ID: 15570685

  46. Tanvetyanon T. Which patient with a do-not-intubate order is a candidate for noninvasive ventilation. Crit Care Med. 2004 Oct;32(10):2148-2150. Pubmedid: 15483429.   Pubmed ID: 15483429

  47. Tanvetyanon T, Leighton J. Life-sustaining treatments in patients who died of chronic congestive heart failure compared with metastatic cancer. Crit Care Med. 2003 Jan;31(1):60-64. Pubmedid: 12544994.   Pubmed ID: 12544994

  48. Tanvetyanon T, Nand S. Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing. Ann Pharmacother. 2003 Dec;37(12):1818-1820. Pubmedid: 14632593.   Pubmed ID: 14632593

  49. Tanvetyanon T, Stadtmauer E, Kerson L. Concurrent administration of interferon alfa-2b and beta-1a. Ann Pharmacother. 2003 Jan;37(1):77-79. Pubmedid: 12503938.   Pubmed ID: 12503938

  50. Tanvetyanon T, Tapaneeyakorn J. Octreotide for bleeding as a result of hepatocellular carcinoma invasion of the gastrointestinal tract. J Gastroenterol Hepatol. 2003 Feb;18(2):231-232. Pubmedid: 12542614.   Pubmed ID: 12542614

  51. Sirisinha T, Ratanatharathorn V, Jirajarus M, Sirilerttrakul S, Silpakit C, Sirachainan E, Tanvetyanon T. The European Organization for Research and Treatment of Cancer quality of life questionnaire: translation and reliability study of the Thai version. J Med Assoc Thai. 2002 Nov;85(11):1210-1219. Pubmedid: 12546319.   Pubmed ID: 12546319

  52. Tanvetyanon T, Leighton J. Severe anemia and marrow plasmacytosis as presentation of Sjogren's syndrome. Am J Hematol. 2002 Mar;69(3):233-233. Pubmedid: 11891816.   Pubmed ID: 11891816

  53. Tanvetyanon T, Walkenstein M, Marra A. Inaccurate glucose determination by fingerstick in a patient with peripheral arterial disease. Ann Intern Med. 2002 Nov;137(9):W1-W1. Pubmedid: 12416976.   Pubmed ID: 12416976

  54. Tanvetyanon T, Dissin J, Selcer U. Hyperthermia and chronic pancerebellar syndrome after cocaine abuse. Arch Intern Med. 2001 Feb;161(4):608-610. Pubmedid: 11252123.   Pubmed ID: 11252123

  55. Tanvetyanon T, Cohn J. Eligibility for outpatient treatment with low-molecular-weight heparin in venous thromboembolism. Arch Intern Med. 2000 Mar;160(6):869-870. Pubmedid: 10737288.   Pubmed ID: 10737288

Tawee Tanvetyanon, MD

Below is a list of active grants where the faculty member is the Principal Investigator. Grants are sorted by sponsor and then sorted by start date, with the more recent grant shown first.

Cisplatin, Bevacizumab & Pemetrexed in the 1st line Treatment in Malignant Pleural Mesothelioma
Sponsor: Genentech, Inc.
Project Dates: October 12, 2006 to October 11, 2010
Annual Direct Cost: $2,307
Annual Total Cost: $2,999
Project Total: $40,484

Zalutumumab in Non-Curable Patients with SCCHN
Sponsor: GenMab A/S
Project Dates: October 25, 2007 to October 24, 2010
Annual Direct Cost: $1,180
Annual Total Cost: $1,235
Project Total: $28,046

Physician/Faculty  Contact Form

© Copyright 1996 - 2010 H. Lee Moffitt Cancer Center & Research Institute